GlassScriptPhysician profile
Michael L Hattan
NPI 1124093232
$8,654.20
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $1,139 · 2021: $1,815 · 2022: $1,615 · 2023: $1,494 · 2024: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $881.46 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $724.46 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $720.79 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $686.94 | 2021-2024 | |
| Pfizer INC. | $663.19 | 2019-2024 | |
| Lilly USA, LLC | $582.66 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.22 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $439.19 | 2019-2024 | Proquad, Vaxneuvance, Gardasil 9 |
| Glaxosmithkline, LLC. | $388.46 | 2019-2023 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $323.66 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $271.47 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $255.66 | 2024 | |
| Esperion Therapeutics, INC. | $228.94 | 2020-2022 | |
| Radius Health, INC. | $223.24 | 2019-2024 | Tymlos |
| Amarin Pharma, INC. | $207.42 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.